The Valley Desk

NCT03264989 · Interventional trial

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Overall registry status Completed

Phase 2

Conditions Sickle Cell Disease (SCD)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov